JD Supra

Appellate Challenges to USPTO’s Discretionary Denial Framework

Since the United States Patent and Trademark Office (USPTO) rescinded former Director Vidal’s 2022 memorandum concerning discretionary denials ...
The Commonwealth Fund

How Drugmakers Use the Patent Process to Keep Prices High

Patent reforms could address a problem that’s been driving rising prescription drug costs and create a more competitive ...
National Law Review

New Continuation Fee Among 2025 USPTO Changes Impacting Biotech

The U.S. Patent and Trademark Office (USPTO) has implemented a Continuation Application Fee (CAF) for certain continuing ...
JD Supra

USPTO Launches Streamlined Patent Application Program

For applicants with a patent application having, or amended to have, a streamlined claim set—one independent claim and a maximum of nine ...

ON24 Announces Third Quarter 2025 Financial Results

ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B marketing, sales, and other customer-facing teams, today ...
National Law Review

Federal Circuit Denies Mandamus - USPTO Discretionary Denial, Fintiv, and Sotera Stipulations in Motorola-Stellar IPRs

The decision concerns eight patents owned by Stellar, LLC that were the subject of Motorola Solutions, Inc.’s inter partes review (IPR) petitions. The Federal Circuit’s analysis focuses on the US ...

Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set

Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and ...